Rep. Eshoo Statement on FDA Authorization of Johnson & Johnson’s COVID-19 Vaccine

February 27, 2021
Press Release

WASHINGTON, D.C. – U.S. Rep. Anna G. Eshoo (CA-18), Chairwoman of the Energy and Commerce Health Subcommittee, released the following statement today after the Food and Drug Administration (FDA) granted an emergency use authorization for Johnson & Johnson’s COVID-19 vaccine:

“With today’s authorization of the Johnson & Johnson vaccine, the U.S. now has three FDA-authorized COVID-19 vaccines that have demonstrated high effectiveness and met rigorous safety standards based on clinical testing. This one-dose vaccine will be a gamechanger in our fight against the pandemic, as millions will be able to access the latest safe and effective COVID-19 vaccine.

“Bravo to the brilliant scientists who developed the vaccine and the career officials at the FDA who ensured it met rigorous standards for safety, effectiveness and manufacturing quality. With 20 million Johnson & Johnson shots available over the next month, and approximately 380,000 doses arriving in California as early as this week, the next vital step is to quickly and equitably distribute the vaccines. Last night, the House of Representatives passed the American Rescue Plan which provides $20 billion to support vaccine distribution in local communities. I look forward to the legislation becoming law soon so we can crush this virus and save lives as soon as possible.”